




# Optimising Prevention of Secondary Stroke



<sup>a</sup> Vascular imaging is recommended in all patients and CTA or MRA from arch to vertex is appropriate for both anterior and posterior circulation stroke.

Kleindorfer DO et al. *Stroke*. 2021;52:e364–e467.

CTA: CT angiography; MRA: MR angiography; SOE: source of embolism; TEE: transesophageal echocardiography.

The information presented here is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment included here should not be used by clinicians without evaluation of their patients' conditions and possible contraindications, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. No endorsement of any products or uses is made or implied by coverage of such in our materials. No responsibility is taken for errors or omissions in our materials.



# Factor XI Inhibitors for Secondary Prevention in Noncardioembolic Stroke: Phase 3 Trials

Trial	OCEANIC-Stroke <sup>a</sup>	LIBREXIA-STROKE <sup>b</sup>
<b>Study design</b>	Randomised, blind, placebo-controlled	Randomised, blind, placebo-controlled
<b>NCT number</b>	NCT05686070	NCT05702034
<b>Study drug</b>	Asundexian 50 mg QD + APT (duration: 3–31 mo)	Milvexian 25 mg BID + SAPT or DAPT
<b>Primary outcome(s)</b>	<ul style="list-style-type: none"> <li>Time to first occurrence of ischaemic stroke</li> <li>Time to first occurrence of major bleeding (ISTH criteria)</li> </ul>	<ul style="list-style-type: none"> <li>Time to first occurrence of ischaemic stroke up to global targeted endpoint date (~41 mo)</li> </ul>
<b>Countries, n</b>	38	54
<b>Sites, n</b>	745	814
<b>Estimated participants, n</b>	12,300	15,000
<b>Estimated study period</b>	2023–2025	2023–2026

<sup>a</sup> **Participant countries:** Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Kazakhstan, Korea (Republic of), Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States of America.

<sup>b</sup> **Participant countries:** Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea (Republic of), Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States of America, Vietnam.

Clinicaltrial.gov: NCT05686070. Last update posted 3 March, 2025. Accessed 18 March, 2025.

Clinicaltrial.gov: NCT05702034. Last update posted: 3 March, 2025. Accessed 18 March, 2025.

(D/S)APT: (dual/single) antiplatelet therapy; ISTH: International Society on Thrombosis and Haemostasis.

The information presented here is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment included here should not be used by clinicians without evaluation of their patients' conditions and possible contraindications, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. No endorsement of any products or uses is made or implied by coverage of such in our materials. No responsibility is taken for errors or omissions in our materials.